1. Home
  2. LARK vs CRBP Comparison

LARK vs CRBP Comparison

Compare LARK & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Landmark Bancorp Inc.

LARK

Landmark Bancorp Inc.

N/A

Current Price

$32.30

Market Cap

190.1M

Sector

Finance

ML Signal

N/A

CRBP

Corbus Pharmaceuticals Holdings Inc.

N/A

Current Price

$4.18

Market Cap

190.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LARK
CRBP
Founded
1885
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
190.1M
190.3M
IPO Year
2001
2014

Fundamental Metrics

Financial Performance
Metric
LARK
CRBP
Price
$32.30
$4.18
Analyst Decision
Strong Buy
Analyst Count
0
10
Target Price
N/A
★ $34.89
AVG Volume (30 Days)
4.3K
★ 860.0K
Earning Date
10-28-2026
11-11-2026
Dividend Yield
★ 2.60%
N/A
EPS Growth
★ 35.84
N/A
EPS
★ 1.70
N/A
Revenue
N/A
★ $4,822,272.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$131.00
P/E Ratio
$18.93
★ N/A
Revenue Growth
N/A
★ 97.62
52 Week Low
$23.57
$3.87
52 Week High
$34.60
$12.88

Technical Indicators

Market Signals
Indicator
LARK
CRBP
Relative Strength Index (RSI) 52.42 24.98
Support Level $30.92 N/A
Resistance Level $32.40 $9.66
Average True Range (ATR) 0.56 0.33
MACD 0.08 0.12
Stochastic Oscillator 50.66 21.94

Price Performance

Historical Comparison
LARK
CRBP

About LARK Landmark Bancorp Inc.

Landmark Bancorp Inc is the bank holding company for Landmark National Bank, which is dedicated to providing quality financial and banking services. The Bank has continued to focus on increasing its originations of commercial, commercial real estate (CRE), and agricultural loans, which management believes will be more profitable and provide more growth for the Bank than traditional one-to-four-family residential real estate lending. In addition, it also invests in certain investment and mortgage-related securities using deposits and other borrowings as funding sources. Its primary deposit gathering and lending markets are geographically diversified with locations in central, eastern, southeast, and Southwest Kansas.

About CRBP Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

Share on Social Networks: